Evercore ISI initiated coverage on West Pharm with a new price target
$WST
Medical/Dental Instruments
Health Care
Evercore ISI initiated coverage of West Pharm with a rating of Outperform and set a new price target of $275.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/15/2025 | $311.00 | Buy | Rothschild & Co Redburn |
| 6/24/2025 | $245.00 | Equal Weight | Barclays |
| 3/18/2025 | $275.00 | Outperform | Evercore ISI |
| 2/14/2025 | $250.00 | Hold → Buy | Deutsche Bank |
| 1/8/2025 | $400.00 | Buy | Citigroup |
| 12/13/2024 | Peer Perform | Wolfe Research | |
| 12/12/2024 | $350.00 → $390.00 | Neutral → Buy | UBS |
| 2/7/2024 | $323.00 → $536.00 | Hold → Buy | Jefferies |
EXTON, Pa., Oct. 27, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the launch of its West Synchrony™ Prefillable Syringe (PFS) System at CPHI Worldwide in Frankfurt, Germany. This innovative system marks a significant shift in drug delivery solutions by offering a fully verified platform from a single supplier that will be commercially available in January 2026. The West Synchrony PFS system delivers a fully verified system-level solution designed specifically for
EXTON, Pa., Oct. 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following upcoming investor conferences: UBS Global Healthcare Conference: Fireside chat at 9:30 AM ET on Tuesday, November 11, 2025, in Palm Beach Gardens, FL.Jefferies Global Healthcare Conference: Fireside chat at 10:00 AM GMT on Tuesday, November 18, 2025, in London, UK.Stephens Annual Investment Conference: Fireside chat at 11:00 AM CT on Thursday, November 20, 2025
- Delivered solid growth across Proprietary Products and Contract Manufacturing Segments - - Achieved double-digit growth in HVP Components -- Strengthened executive leadership team, including recently appointed CFO Robert McMahon -- Increases Full-Year 2025 Revenue and EPS Guidance - EXTON, Pa., Oct. 23, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the third quarter of 2025. Third-Quarter Summary (comparisons to prior-year period)
Rothschild & Co Redburn initiated coverage of West Pharm with a rating of Buy and set a new price target of $311.00
Barclays initiated coverage of West Pharm with a rating of Equal Weight and set a new price target of $245.00
Evercore ISI initiated coverage of West Pharm with a rating of Outperform and set a new price target of $275.00
4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
3 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
SCHEDULE 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
10-Q - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)
- Delivered solid growth across Proprietary Products and Contract Manufacturing Segments - - Achieved double-digit growth in HVP Components -- Strengthened executive leadership team, including recently appointed CFO Robert McMahon -- Increases Full-Year 2025 Revenue and EPS Guidance - EXTON, Pa., Oct. 23, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the third quarter of 2025. Third-Quarter Summary (comparisons to prior-year period)
EXTON, Pa., Oct. 9, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter financial results before the market opens on Thursday, October 23, 2025, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone partici
- Conference Call Scheduled for 8 a.m. EDT Today - EXTON, Pa., July 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the second-quarter 2025 and a fourth-quarter 2025 dividend. Second-Quarter 2025 Summary (comparisons to prior-year period) Net sales of $766.5 million increased 9.2%; organic net sales growth was 6.8%.Diluted EPS of $1.82, compared to $1.51 in the same period last year.Adjusted-diluted EPS of $1.84, compared to $1.52 in the same period last year.Updates full-year 2025 net sales guidance range to $3.
EXTON, Pa., July 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition. "Bob is an accomplished CFO and business executive within the
CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal
EXTON, Pa., May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West's Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead our Global Operations and Global Supply Chain. The Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July 2022 to ensure a seamless transition.